AstraZeneca announced full results from its OBERON and TITANIA Phase 3 trials for tozorakimab. The experimental drug reduced moderate-to-severe COPD flare-ups by approximately 30% compared to a placebo. The New England Journal of Medicine published the data, which evaluated the drug as an add-on to standard inhaled therapy.
Tozorakimab demonstrated efficacy across a broad population, including patients with low blood eosinophil levels. This finding positions the drug as a potential first-in-class biologic for COPD patients currently ineligible for approved treatments.
The U.S. FDA accepted tozorakimab for Priority Review. A regulatory decision is expected in the first quarter of 2027.